The focus of her research career has been to elucidate critical mechanisms responsible for drug resistant breast cancer. The goal of the research laboratory is to identify these critical survival and proliferative pathways to provide novel targets for new therapeutic interventions. Currently, the laboratory is focused on the role and contribution of the Notch signaling pathway in drug resistance to anti-hormonal and anti-ErbB-2 therapies. The critical research objective is to identify, validate, and test novel therapeutics targeting Notch signaling with the expectation of preventing breast tumor resistance, recurrence, progression, and ultimately death-associated with Notch-mediated drug resistance.